Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

BACKGROUND: Biological therapies (BTs) including infliximab (IFX), adalimumab (ADL), secukinumab (SCK) and ustekinumab (UST) are approved in Japan for the treatment of psoriasis. Although the persistence rates and medical costs of BTs treatment have been investigated in multiple foreign studies in r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sruamsiri, Rosarin, Iwasaki, Kosuke, Tang, Wentao, Mahlich, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042444/
https://www.ncbi.nlm.nih.gov/pubmed/29996929
http://dx.doi.org/10.1186/s12895-018-0074-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042444/
https://www.ncbi.nlm.nih.gov/pubmed/29996929
http://dx.doi.org/10.1186/s12895-018-0074-0

Ejemplares similares